Lupin Limited, a prominent global pharmaceutical company, has unveiled the launch of Bromfenac Ophthalmic Solution, 0.075%, following its approval by the United States Food and Drug Administration (U.S. FDA).
This solution serves as a generic equivalent to BromSite® Ophthalmic Solution, 0.075%, developed by Sun Pharmaceutical Industries Limited. It is designed to address postoperative inflammation and alleviate ocular pain in patients undergoing cataract surgery.
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite®) boasted estimated annual sales of USD 15 million in the U.S. market as of December 2023, according to IQVIA.
Lupin is an innovative, transnational pharmaceutical enterprise headquartered in Mumbai, India. The company specializes in the development and commercialization of a diverse portfolio, encompassing branded and generic formulations, biotechnology products, and APIs. Operating in over 100 markets globally, including the U.S., India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East, Lupin holds a leadership position in cardiovascular, anti-diabetic, and respiratory segments. Additionally, it maintains a significant presence in anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health domains. Lupin stands as the third-largest pharmaceutical company in the U.S. based on prescriptions filled. The company’s commitment to innovation is reflected in its substantial investment, allocating 7.9% of its revenue to research and development in FY23. With 15 manufacturing sites, 7 research centers, and a global workforce exceeding 20,000 professionals, Lupin has consistently been acknowledged as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
